A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers
A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
An Observational Study of the Functional Capacity of Heart Failure
Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure
A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure
† Study has passed its completion date and status has not been verified in more than two years.